210 related articles for article (PubMed ID: 31329042)
1. Ral GTPase Activation by Downregulation of RalGAP Enhances Oral Squamous Cell Carcinoma Progression.
Gao P; Liu S; Yoshida R; Shi CY; Yoshimachi S; Sakata N; Goto K; Kimura T; Shirakawa R; Nakayama H; Sakata J; Kawashiri S; Kato K; Wang XY; Horiuchi H
J Dent Res; 2019 Aug; 98(9):1011-1019. PubMed ID: 31329042
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer.
Saito R; Shirakawa R; Nishiyama H; Kobayashi T; Kawato M; Kanno T; Nishizawa K; Matsui Y; Ohbayashi T; Horiguchi M; Nakamura T; Ikeda T; Yamane K; Nakayama E; Nakamura E; Toda Y; Kimura T; Kita T; Ogawa O; Horiuchi H
Oncogene; 2013 Feb; 32(7):894-902. PubMed ID: 22450745
[TBL] [Abstract][Full Text] [Related]
3. Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.
Yoshimachi S; Shirakawa R; Cao M; Trinh DA; Gao P; Sakata N; Miyazaki K; Goto K; Miura T; Ariake K; Maeda S; Masuda K; Ishida M; Ohtsuka H; Unno M; Horiuchi H
Cancer Sci; 2021 Aug; 112(8):3064-3073. PubMed ID: 34009715
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of RalGTPase-Activating Protein Promotes Colitis-Associated Cancer via NLRP3 Inflammasome Activation.
Iida T; Hirayama D; Minami N; Matsuura M; Wagatsuma K; Kawakami K; Nagaishi K; Nojima M; Ikeuchi H; Hirota S; Shirakawa R; Horiuchi H; Nakase H
Cell Mol Gastroenterol Hepatol; 2020; 9(2):277-293. PubMed ID: 31622786
[TBL] [Abstract][Full Text] [Related]
5. Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.
Kidd AR; Snider JL; Martin TD; Graboski SF; Der CJ; Cox AD
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):205-12. PubMed ID: 20619549
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of RalGTPase-activating protein promotes invasion of prostatic epithelial cells and progression from intraepithelial neoplasia to cancer during prostate carcinogenesis.
Uegaki M; Kita Y; Shirakawa R; Teramoto Y; Kamiyama Y; Saito R; Yoshikawa T; Sakamoto H; Goto T; Akamatsu S; Yamasaki T; Inoue T; Suzuki A; Horiuchi H; Ogawa O; Kobayashi T
Carcinogenesis; 2019 Dec; 40(12):1535-1544. PubMed ID: 31058283
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
Tian L; Zhao L; Sze KM; Kam CS; Ming VS; Wang X; Zhang VX; Ho DW; Cheung TT; Chan LK; Ng IO
Hepatology; 2022 Jul; 76(1):48-65. PubMed ID: 34767674
[TBL] [Abstract][Full Text] [Related]
8. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.
Vigil D; Martin TD; Williams F; Yeh JJ; Campbell SL; Der CJ
J Biol Chem; 2010 Nov; 285(45):34729-40. PubMed ID: 20801877
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases.
Shirakawa R; Fukai S; Kawato M; Higashi T; Kondo H; Ikeda T; Nakayama E; Okawa K; Nureki O; Kimura T; Kita T; Horiuchi H
J Biol Chem; 2009 Aug; 284(32):21580-8. PubMed ID: 19520869
[TBL] [Abstract][Full Text] [Related]
10. Low expression of RalGAPs associates with the poorer overall survival of head and neck squamous cell carcinoma.
Liu S; Shi C; Wang X; Ma X; Gao P
Transl Cancer Res; 2021 Dec; 10(12):5085-5094. PubMed ID: 35116360
[TBL] [Abstract][Full Text] [Related]
11. Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC; Oxford G; Baras AS; Owens C; Havaleshko D; Brautigan DL; Safo MK; Theodorescu D
Clin Cancer Res; 2007 Jul; 13(13):3803-13. PubMed ID: 17606711
[TBL] [Abstract][Full Text] [Related]
12. The RAL Enigma: Distinct Roles of RALA and RALB in Cancer.
Richardson DS; Spehar JM; Han DT; Chakravarthy PA; Sizemore ST
Cells; 2022 May; 11(10):. PubMed ID: 35626682
[TBL] [Abstract][Full Text] [Related]
13. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
14. A role for Ral GTPase-activating protein subunit β in mitotic regulation.
Personnic N; Lakisic G; Gouin E; Rousseau A; Gautreau A; Cossart P; Bierne H
FEBS J; 2014 Jul; 281(13):2977-89. PubMed ID: 24814574
[TBL] [Abstract][Full Text] [Related]
15. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
Lim KH; O'Hayer K; Adam SJ; Kendall SD; Campbell PM; Der CJ; Counter CM
Curr Biol; 2006 Dec; 16(24):2385-94. PubMed ID: 17174914
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in silico validation of CA3 and FHL1 downregulation in oral cancer.
Pereira CM; de Carvalho AC; da Silva FR; Melendez ME; Lessa RC; Andrade VCC; Kowalski LP; Vettore AL; Carvalho AL
BMC Cancer; 2018 Feb; 18(1):193. PubMed ID: 29454310
[TBL] [Abstract][Full Text] [Related]
17. Activation of RalA is critical for Ras-induced tumorigenesis of human cells.
Lim KH; Baines AT; Fiordalisi JJ; Shipitsin M; Feig LA; Cox AD; Der CJ; Counter CM
Cancer Cell; 2005 Jun; 7(6):533-45. PubMed ID: 15950903
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma.
Imai T; Toyota M; Suzuki H; Akino K; Ogi K; Sogabe Y; Kashima L; Maruyama R; Nojima M; Mita H; Sasaki Y; Itoh F; Imai K; Shinomura Y; Hiratsuka H; Tokino T
Cancer Sci; 2008 May; 99(5):958-66. PubMed ID: 18294275
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.
Smith SC; Baras AS; Owens CR; Dancik G; Theodorescu D
Cancer Res; 2012 Jul; 72(14):3480-91. PubMed ID: 22586063
[TBL] [Abstract][Full Text] [Related]
20. An integrated methylation and gene expression microarray analysis reveals significant prognostic biomarkers in oral squamous cell carcinoma.
Zhao C; Zou H; Zhang J; Wang J; Liu H
Oncol Rep; 2018 Nov; 40(5):2637-2647. PubMed ID: 30226546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
